Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: FDA Approves Hologic Aptima HPV Assay for Panther System


The US Food and Drug Administration has approved Hologic's Aptima HPV assay for use on the company's fully automated Panther system.

The Aptima HPV test is performed with Hologic's ThinPrep liquid cytology specimen and can be tested before and after it has been processed for cytology testing on the ThinPrep 2000 system.

The assay is a nucleic acid amplification test that detects mRNA overexpressed from the E6 and E7 viral oncogenes in 14 high-risk human papillomavirus types associated with cervical cancer and precancerous lesions. The test has demonstrated significantly improved specificity with no compromise in disease detection.

FDA approved the assay for two uses: to determine the need for referral to colposcopy for women 21 years and older whose cervical cytology results indicated atypical squamous cells of undetermined significance; and to use adjunctively with cervical cytology to screen women 30 years and older to assess the presence or absence of high-risk HPV types.

The Aptima HPV assay was CE marked in 2008 and received FDA approval on Gen-Probe's high-throughput Tigris system in 2011, prior to Hologic's acquisition of Gen-Probe.

The addition of the Aptima HPV assay to the Panther menu extends the capability of low- to high-volume laboratories to run multiple tests from a single specimen on a cost-effective, highly flexible, and fully automated molecular testing platform, Hologic said.

Created to be a "sample-in-result-out" instrument, the Panther eliminates batch processing and automates all aspects of nucleic acid testing on a single, integrated platform.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.